2012 Comment Letters

In July 2023, we changed our name from AACC (short for the American Association for Clinical Chemistry) to the Association for Diagnostics & Laboratory Medicine (ADLM). The following page links to resources that were written prior to the rebranding and/or mentions events that took place prior to the rebranding and that contain mentions of the association’s old name.

AACC continually tracks legislative and regulatory issues of importance to clinical laboratories and the clinical laboratory profession. This is a listing of AACC 's 2012 comment letters. AACC commented on a wide range of topics to federal and state authorities.

Legislative issues

AACC joins with the Clinical Laboratory Coalition in opposing additional cuts in laboratory payments

NOV.29.2012

AACC endorses H.R.6118, the "Taking Essential Steps for Testing Act," which would give CMS more flexibility in assessing penalties for violating the CLIA PT referral provisions

AUG.01.2012

AACC supports full federal funding for the NIH National Children's Study

JUL.30.2012

AACC urges legislators to oppose the elimination of funding for the Agency for Healthcare Research and Quality

JUL.30.2012

AACC joins with the Clinical Laboratory Coalition in seeing the repeal of the forthcoming medical device tax

JUN.06.2012

AACC opposes inclusion of LDT legislation in FDA user fee legislation

MAY.21.2012

AACC supports House changes to the de novo process

MAY.16.2012

AACC supports Senate changes to the de novo process

MAY.09.2012

AACC supports congressional involvement regarding the FDA June 2011 RUO/IUO draft guidance

MAY.01.2012

AACC joins with the Friends of AHRQ in supporting additional research funding for AHRQ

MAR.19.2012

AACC, as part of the DC Principles Coalition, opposes legislation that gives the government a greater role in determining when private sector articles are made free to the public

MAR.05.2012

AACC supports continued funding for the National Children's Study

FEB.28.2012

AACC opposes legislation that would eliminate the Patient-Centered Outcomes Research Institute

FEB.28.2012

AACC seeks answers regarding the impact of congressional legislation on patient access to laboratory developed tests

FEB.16.2012

AACC and the Clinical Laboratory Coalition opposes proposed cuts in laboratory reimbursement

FEB.15.2012

AACC supports congressional efforts to streamline the FDA's de novo process

FEB.02.2012

Regulatory issues

AACC writes to CMS recommendation revisions to the draft Individualized Quality Control Plan

OCT.10.2012

AACC writes to the State of Massachusetts urging support for harmonization efforts

SEP.19.2012

AACC writes to CMS suggesting that most molecular codes remain on the clinical laboratory fee schedule

SEP.18.2012

AACC urges CMS to consider technology when determining which fee schedule to place the new molecular codes

AUG.08.2012

AACC wrote to CMS opposing the placement of all molecular codes on a single fee schedule

JUL.12.2012

AACC provided CMS with input regarding the payment amounts for the new 2013 CPT codes

JUL.12.2012

AACC provided input to the FDA regarding the design and performance of indwelling continuous blood glucose monitors

JUN.25.2012

AACC submits comment to CMS regarding March 7, 2012 CMS proposed rule regarding electronic health record incentive payments

MAY.07.2012

AACC provides input to the Patient-Centered Outcomes Research Institute regarding its research agenda

MAR.14.2012

AACC supports the Joint Commission's efforts to reduce inappropriate test utilization>AACC supports the Joint Commission's efforts to reduce inappropriate test utilization

JAN.20.2012